Oncologic Outcomes of Laparoscopic Radical Nephroureterectomy in Conjunction with Template-based Lymph Node Dissection: An Extended Follow-up Study
Overview
Authors
Affiliations
Objectives: This study investigated the relapse pattern and oncologic outcomes after laparoscopic nephroureterectomy with template-based lymph node dissection (LND) in patients with clinically node-negative (cN0) upper urinary tract urothelial carcinoma. The frequency of lymph node metastasis, including micrometastases, was also evaluated.
Methods And Materials: A total of 105 patients with cTa-3N0M0 upper urinary tract urothelial carcinoma were analyzed, all of whom underwent regional LND during laparoscopic nephroureterectomy. Of those patients, 96 (91%) underwent complete LND in accordance with an anatomical template-based rule. We collected patient characteristics, pathological data, and follow-up data from medical charts. Micrometastases were assessed by pan-cytokeratin immunohistochemistry. Nonurothelial recurrence-free survival and cancer-specific survival were estimated using the Kaplan-Meier method.
Results: The median number of lymph nodes removed was 12 (range, 1-59). Lymph node metastasis was identified by routine pathological examination in 7 (7/105, 6.7%) patients. Pan-cytokeratin immunohistochemistry revealed micrometastases in 5 additional patients (pNmicro +: 5/105, 4.8%). Nonurothelial disease recurrence was observed in 21 (20%) patients at a median of 10 months (range: 1-33) after surgery. Distant metastasis was dominant (15/105, 14.3%), followed by locoregional recurrence (5/105, 4.8%) and both (1/105, 0.95%). The 5-year nonurothelial recurrence-free survival rates were 84.8% for pN0, 53.3% for pNmicro+, and 19.1% for pN+ (3-sample log-rank test, P < 0.0001). The 5-year cancer-specific survival rates were 95.0% for pN0, 53.3% for pNmicro+, and 23.8% for pN+ (P < 0.0001).
Conclusions: Our observation showed that template-based LND could contribute to precise disease staging and better local disease control probably by eliminating nodal disease, compared with previous studies. The survival impact and ideal management of pNmicro+ disease should be evaluated in a larger cohort.
Ali Deb A, Agag A, Naushad N, Hartley A, Serag H Urol Res Pract. 2023; 49(6):345-359.
PMID: 37982446 PMC: 10765198. DOI: 10.5152/tud.2023.23045.
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.
Dlubak A, Karwacki J, Logon K, Tomecka P, Brawanska K, Krajewski W Curr Oncol Rep. 2023; 25(11):1327-1344.
PMID: 37801187 PMC: 10640513. DOI: 10.1007/s11912-023-01460-y.
Lee H, Chang C, Huang C, Yu C, Lo C, Chung S Front Oncol. 2022; 12:791620.
PMID: 35574295 PMC: 9099435. DOI: 10.3389/fonc.2022.791620.
Peyrottes A, Califano G, Ouzaid I, Laine-Caroff P, Long Depaquit T, Hermieu J Front Surg. 2022; 9:852969.
PMID: 35402485 PMC: 8987284. DOI: 10.3389/fsurg.2022.852969.